Preview

Научно-практическая ревматология

Расширенный поиск

Вакцинация в ревматологии: современные аспекты

https://doi.org/10.14412/1995-4484-2014-660-668

Полный текст:

Аннотация

Инфекционные заболевания по-прежнему остаются серьезной социальной и медицинской проблемой. В ревматологии значимость коморбидных инфекций за последнее время существенно увеличилась, особенно в связи с внедрением в клиническую практику генно-инженерных биологических препаратов. Одним из путей решения указанной проблемы является изучение и активное применение различных вакцин. В настоящем обзоре рассмотрены вопросы, касающиеся применения вакцин против гриппа, инфекций, обусловленных пневмококками, вирусами герпеса, папилломы человека и гепатита В у ревматологических больных. Обсуждаются безопасность и иммуногенность вакцинации, связанной с предупреждением инфекций дыхательных путей как наиболее частой причины неблагоприятного исхода при ревматических заболеваниях. Обозначены основные направления будущих исследований по рассматриваемой проблеме.

Об авторах

Б. С. Белов
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия

руководитель лаборатории изучения роли инфекции при ревматических заболеваниях ФГБНУ им. В.А. Насоновой, докт. мед. наук



М. С. Наумцева
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия

аспирант ФГБНУ им. В.А. Насоновой



Г. М. Тарасова
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия

старший сотрудник лаборатории изучения роли инфекции при ревматических заболеваниях ФГБНУ им. В.А. Насоновой, канд. мед. наук



М. В. Полянская
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия

научный сотрудник лаборатории изучения роли инфекции при ревматических заболеваниях ФГБНУ им. В.А. Насоновой, канд. мед. наук



Список литературы

1. Белов БС, Балабанова РМ, Манукян СГ и др. Коморбидные инфекции при ревматических заболеваниях. Тезисы доклада международной конференции ревматологов. Чимкент; 2006. С. 17. [Belov BS, Balabanova RM, Manukyan SG, et al. Komorbidny infections at rheumatic diseases. In: Tezisy doklada mezhdunarodnoi konferentsii revmatologov [Theses of the report of the international conference of rheumatologists]. Chimkent, 2006. P. 17.]

2. Wolfe F, Mitchell DM, Sibley JT. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–94. DOI: http://dx.doi.org/10.1002/art.1780370408.

3. Edwards CJ, Lian TY, Badsha H, et al. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 2003;12(9):672–6. DOI: http://dx.doi.org/10.1191/0961203303lu452oa.

4. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15. DOI: http://dx.doi.org/10.1136/ard.2009.114264.

5. Решетняк ТМ. Антифосфолипидный синдром: клиника, диагностика и вопросы патогенеза. Автореф. дисс. ... докт. мед. наук. Москва; 1999. 57 с. [Reshetnyak TM. Antifosfolipidnyi sindrom: klinika, diagnostika i voprosy patogeneza. Avtoref. diss… dokt. med. nauk [Antifosfolipidny syndrome: clinic, diagnostics and questions of pathogenesis: Dr. Diss. (Med. Sci.)]. Moscow; 1999. 57 p.]

6. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome – molecular mimicry? J Rheumatol. 2000;27(1):12–4.

7. Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–22. DOI: http://dx.doi.org/10.1136/ard.2010.137216.

8. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39. DOI: http://dx.doi.org/10.1002/acr.21641.

9. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–100. DOI: http://dx.doi.org/10.1093/cid/cit684.

10. Lanternier F, Henegar C, Mouthon L, et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis. 2008;67(7):1047. DOI: http://dx.doi.org/10.1136/ard.2007.081703.

11. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(6):837–8. DOI: http://dx.doi.org/10.1136/ard.2006.060285.

12. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62–8. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204223.

13. Lawson EF, Trupin L, von Scheven E, et al. Reasons for failure to obtain influenza and pneumococcal vaccines among immunosuppressed individuals with systemic lupus erythematosus. Arthritis Rheum. 2013;65(10 Suppl)362.

14. Williams GW, Steinberg AD, Reinertsen JL, et al. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med. 1978;88(6):729–34. DOI: http://dx.doi.org/10.7326/0003-4819-88-6-729.

15. Brodman R, Gilfillan R, Glass D, Schur PH. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):735–40. DOI: http://dx.doi.org/10.7326/0003-4819-88-6-735.

16. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):790–2. DOI: http://dx.doi.org/10.7326/0003-4819-88-6-790.

17. Ristow SC, Douglas RG Jr, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med. 1978;88(6):786–9. DOI: http://dx.doi.org/10.7326/0003-4819- 88-6-786.

18. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 1979;242(1):53–6. DOI: http://dx.doi.org/10.1001/jama.1979.03300010037025.

19. Holvast A, van Assen S, de Haan A, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2438–47. DOI: http://dx.doi.org/10.1002/art.24679.

20. Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford). 2009;48(10):1294–9. DOI: http://dx.doi.org/10.1093/rheumatology/kep200.

21. Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S83–9.

22. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158. DOI: http://dx.doi.org/10.1186/1471-2474-13-158.

23. Miraglia JL, Abdala E, Hoff PM, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One. 2011;6(11):e27214. DOI: http://dx.doi.org/10.1371/journal.pone.0027214.

24. Franca IL, Ribeiro AC, Aikawa NE, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford). 2012;51(11):2091–8. DOI: http://dx.doi.org/10.1093/rheumatology/kes202.

25. Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with antitumor necrosis factor. Arthritis Res Ther. 2011;13(6):R209. http://dx.doi.org/10.1186/ar3542.

26. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol. 2010;134(2):113–20. DOI: http://dx.doi.org/10.1016/j.clim.2009.09.014.

27. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713–6. DOI: http://dx.doi.org/10.1136/ard.2007.077552.

28. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010;39(6):442–7. DOI: http://dx.doi.org/10.1016/j.semarthrit.2008.12.002.

29. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63(6):1486–96. DOI: http://dx.doi.org/10.1002/art.30325.

30. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34(2):272–9.

31. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65(2):191–4. DOI: http://dx.doi.org/10.1136/ard.2005.036434.

32. Kivitz AJ, Schechtman J, Texter M, et al. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol. 2014;41(4):648–57. DOI: http://dx.doi.org/10.3899/jrheum.130945.

33. Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012;71(12):2006–10. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201950.

34. Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24(3):511–6. DOI: http://dx.doi.org/10.3109/14397595.2013.843743.

35. Ribeiro AC, Laurindo IM, Guedes LK, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65(3):476–80. DOI: http://dx.doi.org/10.1002/acr.21838.

36. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease – a prospectively controlled vaccination study. Rheumatology (Oxford). 2012;51(4):695–700. DOI: http://dx.doi.org/10.1093/rheumatology/ker389.

37. Genovese MC, Bingham CO, Cohen S, et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving subcutaneous abatacept. Arthritis Rheum. 2013;65(10 Suppl):198.

38. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643–8. DOI: http://dx.doi.org/10.1016/j.vaccine.2010.12.072.

39. Rehnberg M, Brisslert M, Amu S, et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010;12(3):R111. DOI: http://dx.doi.org/10.1186/ar3047.

40. Van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81. DOI: http://dx.doi.org/10.1002/art.25033.

41. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–41. DOI: http://dx.doi.org/10.1136/ard.2007.077461.

42. Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33(2):388–96. DOI: http://dx.doi.org/10.1007/s10875-012-9813-x.

43. Westra J, van Assen S, Wilting KR, et al. Rituximab impairs IgM and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014 Jun 2. DOI: http://dx.doi.org/10.1111/cei.12390.

44. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2014;66(7):1016–26. DOI: http://dx.doi.org/10.1002/acr.22246.

45. Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of antirheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014;16(1):R2. DOI: http://dx.doi.org/10.1186/ar4427.

46. Shinjo SK, de Moraes JC, Levy-Neto M, et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease. Vaccine. 2012;31(1):202–6. DOI: http://dx.doi.org/10.1016/j.vaccine.2012.10.063.

47. Setti M, Fenoglio D, Ansaldi F, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine. 2009;27(25–26):3367–72. DOI: http://dx.doi.org/10.1016/j.vaccine. 2009.01.078.

48. Litinsky I, Balbir A, Zisman D, et al. Vaccination against influenza in patients with systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):S7–11.

49. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012;66(12):1177–81. DOI: http://dx.doi.org/10.1136/jech-2011-200168.

50. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, et al. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006;35:273–6. DOI: http://dx.doi.org/10.1080/03009740600556258.

51. Juarez M, Misischia R, Alarcon GA. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/ dermatomyositis. Rheum Dis Clin N Am. 2003;29:163–84. DOI: http://dx.doi.org/10.1016/S0889- 857X(02)00100-X.

52. Nossent J, Cices N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus. 2007;16:309–17. DOI: http://dx.doi.org/10.1177/0961203307077987.

53. Narata R, Wangkaew S, Kasitanon N, Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health. 2007;38(3):528–36.

54. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? J Rheumatol. 2006;33(8):1469–71.

55. Kapetanovic MC, Saxne T, Sjö holm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):106–11. DOI: http://dx.doi.org/10.1093/rheumatology/ kei193.

56. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–6. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-202658.

57. Bingham CO 3rd, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2014 Jan 21. DOI: http://dx.doi.org/10.1136/annrheumdis-2013-204427.

58. Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74. DOI: http://dx.doi.org/10.1002/art.25034.

59. Crnkic Kapetanovic M, Saxne T, Jö nsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. DOI: http://dx.doi.org/10.1186/ar4358.

60. Schiff M, Kaell A, Tay L, et al. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the arrive trial. Ann Rheum Dis. 2007;66(Suppl II):437.

61. Pham T, Claudepierre P, Constantin A, et al. Abatacept therapy and safety management. Joint Bone Spine. 2009;76(Suppl 1):S3–55. DOI: http://dx.doi.org/10.1016/S1297-319X(09)74520-8.

62. Наумцева МС, Белов БС, Тарасова ГМ и др. Клиническая эффективность и безопасность 23-валентной пневмококковой вакцины у больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(Приложение 1):80. [Naumtseva MS, Belov BS, Tarasova GM, et al. Clinical efficiency and safety of a 23-valent pnevmokokkovy vaccine at patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(Suppl 1):80. (In Russ.)].

63. Mercado U, Acosta H, Diaz-Molina R. Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis. J Rheumatol. 2009;36(7):1549–50. DOI: http://dx.doi.org/10.3899/jrheum.081227.

64. Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheumatol. 2009;21(4):419–24. DOI: http://dx.doi.org/10.1097/BOR.0b013e328329ec6e.

65. Salemi S, D'Amelio R. Are anti-infectious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010;29(3):270–314. DOI: http://dx.doi.org/10.3109/08830185.2010.483028.

66. Brezinschek HP, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol. 2008;20(3):295–9. DOI: http://dx.doi.org/10.1097/BOR.0b013e3282ffdeca.

67. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. DOI: http://dx.doi.org/10.1002/art.27233.

68. Wung PK, Holbrook JT, Hoffman GS, et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med. 2005;118(12):1416. DOI: http://dx.doi.org/10.1016/j.amjmed.2005.06.012.

69. Curtis JR, Yang S, Chen L, et al. Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination. Ann Rheum Dis. 2014;73(Suppl 2):452. DOI: http://dx.doi.org/10.1136/annrheumdis-2014-eular.5983.

70. Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. Rheumatol Int. 2006;27(1):67–71. DOI: 0.1007/s00296-006-0165-9.

71. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364–71. DOI: http://dx.doi.org/10.1086/598331.

72. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44. DOI: http://dx.doi.org/10.1001/jama.2009.146.

73. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(4):379–80. DOI: http://dx.doi.org/10.1016/j.jbspin.2014.04.003.

74. Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40(11):1875–80. DOI: http://dx.doi.org/10.3899/jrheum.130170.

75. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9. DOI: http://dx.doi.org/10.1001/jama.2012.7304.

76. Ferreira I, Isenberg D. Vaccines and biologics. Ann Rheum Dis. 2014 Aug;73(8):1446–54. DOI: http://dx.doi.org/10.1136/annrheumdis-2014-205246.

77. Duchet-Niedziolka P, Coutsinos Z, Hanslik T, Launay O. Anti-TNF alpha therapy and vaccination of adults. Joint Bone Spine. 2007;74(6):563–5. DOI: http://dx.doi.org/10.1016/j.jbspin.2007.08.001.

78. Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014;16(8):431. DOI: http://dx.doi.org/10.1007/s11926-014-0431-x.

79. Назарова НМ, Прилепская ВН, Суламанидзе ЛА и др. Папилломавирусная инфекция: распространенность, диагностика и лечение (обзор литературы). Лечащий врач. 2013;11:15–9. [Nazarova NM, Prilepskaya VN, Sulamanidze LA, et al. Papillomavirusny infection: prevalence, diagnostics and treatment (review of literature). Lechashchy vrach. 2013;11:15–9. (In Russ.)]

80. Wheeler CM, Hunt WC, Schiffman M, et al. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194(9):1291–9. DOI: http://dx.doi.org/10.1086/507909.

81. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485–91. DOI: http://dx.doi.org/10.1177/0961203310372952.

82. Lyrio LD, Grassi MF, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):335–40. DOI: http://dx.doi.org/10.1007/s00296-012-2426-0.

83. Santana IU, do Nascimento Gomes A, d’Cirqueira Lyrio L, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011;30(5):665–72. DOI: http://dx.doi.org/10.1007/s10067-010-1606-0.

84. Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol. 2004;31(9):1763–7.

85. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659–64. DOI: http://dx.doi.org/10.1136/annrheumdis-2012-201393.

86. Baranda L, Alvarez-Quiroga C, Gonzalez-Amaro R, et al. Immune effects of human papilloma virus (HPV) immunization in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis. 2014;73(Suppl 2):539. DOI: http://dx.doi.org/10.1136/annrheumdis-2014-eular.5934.

87. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013;11:29. DOI: http://dx.doi.org/10.1186/1546-0096-11-29.

88. Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res. 2010;62(6):749–54. DOI: http://dx.doi.org/10.1002/acr.20130.

89. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21(6):621–7. DOI: http://dx.doi.org/10.1007/s10165-011-0458-z.

90. Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21(1):16–23. DOI: http://dx.doi.org/10.1007/s10165-010-0337-z.

91. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169–75. DOI: http://dx.doi.org/10.1007/s10067-012- 1988-2.

92. Шекшина ЕВ, Балабанова РМ. Инфекция и ревматоидный артрит: некоторые аспекты диагностики и лечения. Инфекция и антимикробная терапия. 2003;5(3):3–8. [Shekshina EV, Balabanova RM. Infection and rheumatoid arthritis: some aspects of diagnostics and treatment. Infektsiya i antimikrobnaya terapiya. 2003;5(3):3–8. (In Russ.)]

93. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(7):623–5. DOI: http://dx.doi.org/10.1136/ard.61.7.623.

94. Alvarez MM, Fernandes CG, Exposito AG. Antibody response to the standard hepatitis B vaccination in patients with rheumatoid arthritis an ankylosing spondilitis treated with infliximab. Arthritis Rheum. 2011;63(10 Suppl 1):515.


Для цитирования:


Белов Б.С., Наумцева М.С., Тарасова Г.М., Полянская М.В. Вакцинация в ревматологии: современные аспекты. Научно-практическая ревматология. 2014;52(6):660-668. https://doi.org/10.14412/1995-4484-2014-660-668

For citation:


Belov B.S., Naumtseva M.S., Tarasova G.M., Polyanskaya M.V. VACCINATION IN RHEUMATOLOGY: CURRENT ASPECTS. Rheumatology Science and Practice. 2014;52(6):660-668. (In Russ.) https://doi.org/10.14412/1995-4484-2014-660-668

Просмотров: 653


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)